New Anaphylm sublingual epinephrine data address FDA’s concerns

Multiple human factors improved following revision of the packaging design and instructions for use on Anaphylm sublingual epinephrine film, according to topline results.As Healio previously reported, the FDA cited concerns about human factors in the use of Aquestive Therapeutics’ Anaphylm (dibutepinephrine) for anaphylaxis and other type 1 allergic reactions in its complete response letter